Blog
RSS FeedPosted by Michael Wonder on 16 Oct 2018
Proposal to award sole supply and change some anti-retroviral brands
16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...
Posted by Michael Wonder on 13 Jul 2018
Gilead receives approval in Canada for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection
12 July 2018 - Gilead Sciences Canada today announced that Health Canada has granted a notice of compliance for Biktarvy (bictegravir ...
Posted by Michael Wonder on 07 Jun 2018
Rapid rise in anti-HIV PrEP pills linked to drop in condom use
7 June 2018 - PrEP availability may play a part in men’s complacency about the chances of becoming infected, study suggests. ...
Posted by Michael Wonder on 21 Mar 2018
New medicine to help end the transmission of HIV
21 March 2018 - The Australian Government is taking a critical step in helping end the transmission of HIV infection in ...
Posted by Michael Wonder on 20 Oct 2017
National PreP service would be cost effective, research finds
20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting ...
Posted by Michael Wonder on 14 Sep 2016
TGA approves Odefsey
30 August 2016 - The TGA has approved Gilead's combination product for HIV-1 infection Odefsey. ...
Posted by Michael Wonder on 13 Sep 2016
Janssen submits marketing authorisation application for darunavir-based single tablet regimen for treatment of HIV-1 to European Medicines Agency
12 September 2016 - Janssen today announced the submission of a Marketing Authorisation Application to the EMA, seeking approval for ...
Posted by Michael Wonder on 09 Sep 2016
Proposal relating to two HIV treatments (Tivicay and Kivexa)
9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)
24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection. ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of Truvada for PrEP
24 August 2016 - The recommendation comes with conditions. ...
Posted by Michael Wonder on 23 Aug 2016
Brisbane sees 30% drop in HIV infection over 5 year period; HIV medicine Truvada still not on PBS
23 August 2016 - The combination HIV medicines that has led to a significant drop in the number of HIV cases ...
Posted by Michael Wonder on 22 Aug 2016
European Commission grants marketing authorization for Gilead’s once-daily Truvada for reducing the risk of sexually acquired HIV-1
22 August 2016 - Truvada is the first anti-retroviral medicine to be licensed in Europe for pre-exposure prophylaxis, in combination with ...
Posted by Michael Wonder on 19 Aug 2016
HIV prevention drug Truvada won't be subsidised in Australia anytime soon
19 August 2016 - An expensive combination product that prevents people from getting HIV won't be funded by taxpayers in Australia ...
Posted by Michael Wonder on 15 Aug 2016
Emtricitabine with tenofovir alafenamide fumarate in HIV infection: additional benefits not covered
15 August 2016 - Deviation from the appropriate comparator therapy/higher loss for certain patients. ...
Posted by Michael Wonder on 02 Aug 2016
Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...